NASDAQ:CATB
Delisted

Catabasis Pharmaceuticals Stock Signals

$3.36
+0.195 (+6.16%)
At Close: May 27, 2022

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 194 days ( 61.82 % )
Last Price $3.36 6.16 %
High/ Low $3.16 - $3.37 0.316%
Chg 7 Days -0.592 % $3.38 $3.36
Chg 30 Days -43.22 % $5.92 $3.36
Chg 12 mos 59.24 % $2.11 $3.36
Trend - 3 mos -38.47 % Width: 96.45 %
Trend - 12 mos 30.20 % Width: 284.99 %
Pred. range - 3 mos $1.65 - $3.24 -50.88 % - -3.50 %
Pred. range - 12 mos $4.10 - $15.79 22.04 % - 369.83 %
Short MA avg 3 mos Buy 2022-05-26 - 2 days
Long MA avg 3 mos Sell 2022-04-08 - 35 days
Short/Long MA avg 3 mos Sell 2022-04-08 - 35 days
Short MA avg 12 mos Buy 2022-04-29 - 21 days
Long MA avg 12 mos Buy 2022-04-06 - 37 days
Short/Long MA avg 12 mos Sell 2022-01-05 - 100 days
Pivot Short Buy 2022-05-24 - 4 days
Bollinger Sell 0000-00-00 - N/A days
MACD Sell No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy (DMD); CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia i... CATB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT